[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603144":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":58,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":25,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":82,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Amino acid mixture infusion with standard of care","EXPERIMENTAL","Continuous infusion of a L-amino acids mixture in a dose of 2 g\u002Fkg dry body weight\u002Fday (to a maximum 100 g\u002Fday) after induction of anesthesia and insertion of CVP line till 72 hours after treatment initiation",[13,14],"Drug: L-Amino acid mixture","Other: Standard of care",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard care","ACTIVE_COMPARATOR","Standard peri liver transplant care as per our institution",[14],[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","L-Amino acid mixture",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Standard of care","Standard peri tranplant care as per out institution including intra operative and post operative care. Its includes starting of immunosuppression after serial blood investigation monitoring.",[9,16],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Ravi Roshan","CONTACT","+91 8010396811","raviroshan10011994@gmail.com",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Nilesh Patil","+91 99115 94576","dr.nils.p@gmail.com",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Ilbs Hospital, D1 Vasant Kunj, New Delhi","New Delhi","National Capital Territory of Delhi","110070","India","IN",{"type":49,"coordinates":50},"Point",[51,52],77.2148,28.62137,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":25,"email":35},"Ravi Roshan, MBBS, MS","8010396811",{"type":59,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100603144","the-efficacy-of-intravenous-amino-acids-in-reducing-the-occurrence-of-aki-after-live-donor-liver-transplant-100603144",false,"NCT07132697","The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant","The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant: An Open Label Randomized Trial","Inclusion Criteria\n\n1. All LDLT Recipient\n2. Age: \\> 18 years\n3. Signed informed consent\n\nExclusion Criteria\n\n1. Negative consent.\n2. Pediatric LDLT.\n3. ALF patient undergoing LDLT.\n4. Patients on intermittent or continuous renal replacement therapy.\n5. Patients with eGFR less then 40 ml per min per 1.73 m2.\n6. SLKT and prior Kidney transplant.\n7. Patient has a hypersensitivity (known allergy) to one or more of the included amino acids.\n8. Patient has a known congenital alteration of amino acid metabolism.","ALL","18 Years","70 Years",{"count":71,"type":72},100,"ESTIMATED","INTERVENTIONAL",[75],"NA","This prospective, open-label, randomized controlled trial aims to evaluate the efficacy of intravenous amino acid infusion in reducing AKI after LDLT. Eligible adult patients undergoing LDLT will be randomized into two groups: one receiving Continuous infusion of a L-amino acids mixture in a dose of 2 g\u002Fkg dry body weight\u002Fday (to a maximum 100 g\u002Fday) after induction of anesthesia and insertion of CVP line till 72 hours after treatment initiation, and the other receiving standard management. The primary outcome is the incidence of AKI as per KDIGO criteria within 7 days of transplant.",[78,79],"Liver Transplant; Complications","AKI - Acute Kidney Injury",[81],"Liver Transplantation, Acute Kidney Injury, Amino Acids, KDIGO, NGAL, Randomized Controlled Trial","NOT_YET_RECRUITING","2025-08-13",{"date":85,"type":86},"2025-08-20","ACTUAL",{"date":88,"type":72},"2025-08-25",{"date":90,"type":72},"2026-09-01",{"name":5,"class":6},1]